Conference Reports for NATAP

EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom  April 9-13 Back

Dose-dependent Pharmacokinetics for MK-5172 25 mg, 50 mg, and 100 mg Once Daily for 12 Weeks in HCV Genotype 1 Treatment-naïve Non-cirrhotic Patients       Reported by Jules Levin EASL 2014 April 9-13 London, UK   Luzelena Caro, Jennifer Talaty, Matias Morrison, Shuping Zhang, Zifang Guo, Isaias Noel Gendrano III, Peggy Hwang, Niloufar Mobashery Merck & Co., Inc., Whitehouse Station NJ, USA